Cantor Fitzgerald Reiterates Overweight on Vera Therapeutics, Maintains $107 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Pete Stavropoulos has reiterated an Overweight rating on Vera Therapeutics (NASDAQ:VERA) and maintained a price target of $107.
September 23, 2024 | 12:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on Vera Therapeutics, maintaining a $107 price target, indicating confidence in the company's potential.
The reiteration of an Overweight rating and a high price target by a reputable analyst suggests positive sentiment and potential upside for Vera Therapeutics' stock. This could lead to increased investor interest and buying pressure, positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100